grade
pharmaceutical primary standard
API family
sulbactam
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
[Na+].[S]1(=O)(=O)[C@H]2N([C@H](C1(C)C)C(=O)[O-])C(=O)C2
InChI
1S/C8H11NO5S.Na/c1-8(2)6(7(11)12)9-4(10)3-5(9)15(8,13)14;/h5-6H,3H2,1-2H3,(H,11,12);/q;+1/p-1/t5-,6+;/m1./s1
InChI key
NKZMPZCWBSWAOX-IBTYICNHSA-M
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Sulbactam sodium EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
法规信息
监管及禁止进口产品
此项目有
In vitro susceptibilities of clinical isolates of Escherichia coli and Klebsiella species to CSE1034 and other β-lactams.
Manu Chaudhary et al.
The Journal of antibiotics, 66(8), 495-497 (2013-04-25)
Alaa A Hassan et al.
Archiv der Pharmazie, 346(7), 562-570 (2013-06-19)
(E)-4-Aryl-2-[2-(1-substituted ethylidene)hydrazinyl]thiazoles and (Z)-3-substituted-4-aryl-2-[(E)-(1-phenylethylidene)hydrazono]-2,3-dihydrothiazoles were synthesized by the reaction of (substituted ethylidene)hydrazinecarbothioamides with ω-bromoacetophenones. The characterization of this new class of compounds was performed using different spectroscopic tools. The structure of (Z)-3-benzyl-4-(4-bromophenyl)-2-[(E)-(1-phenylethylidene)hydrazono]-2,3-dihydrothiazole 6e was unambiguously confirmed by single-crystal X-ray crystallography.
Maura S de Oliveira et al.
Clinics (Sao Paulo, Brazil), 68(4), 569-573 (2013-06-20)
The objective of this study was to evaluate whether the outcomes of carbapenem-resistant Acinetobacter infections treated with ampicillin/sulbactam were associated with the in vitro susceptibility profiles. Twenty-two infections were treated with ampicillin/sulbactam. The median treatment duration was 14 days (range:
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| Y0000529 | 04061837568909 |